Body composition changes after testosterone replacement therapy following spinal cord injury and aging: a mini review

Research output: Contribution to journalReview articlepeer-review

Standard

Body composition changes after testosterone replacement therapy following spinal cord injury and aging : a mini review. / Nightingale, Tom; Moore, Pam; Harman, Joshua; Khalil, Refka; Gill, Ranjodh; Castillo, Teodoro; Adler, Robert; Gorgey, Ashraf.

In: Journal of Spinal Cord Medicine, Vol. 41, No. 6, 02.11.2018, p. 624-636.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Author

Nightingale, Tom ; Moore, Pam ; Harman, Joshua ; Khalil, Refka ; Gill, Ranjodh ; Castillo, Teodoro ; Adler, Robert ; Gorgey, Ashraf. / Body composition changes after testosterone replacement therapy following spinal cord injury and aging : a mini review. In: Journal of Spinal Cord Medicine. 2018 ; Vol. 41, No. 6. pp. 624-636.

Bibtex

@article{427d98ae5f2c46e1b3a983ed2fafc66b,
title = "Body composition changes after testosterone replacement therapy following spinal cord injury and aging: a mini review",
abstract = "CONTEXT: Hypogonadism is a male clinical condition in which the body does not produce enough testosterone. Testosterone plays a key role in maintaining body composition, bone mineral density, sexual function, mood, erythropoiesis, cognition and quality of life. Hypogonadism can occur due to several underlying pathologies during aging and in men with physical disabilities, such as spinal cord injury (SCI). This condition is often under diagnosed and as a result, symptoms undertreated. METHODS: In this mini-review, we propose that testosterone replacement therapy (TRT) might be a viable strategy to improve lean body mass (LBM) and fat mass (FM) in men with SCI. EVIDENCE SYNTHESIS: Supplementing the limited data from SCI cohorts with consistent findings from studies in non-disabled aging men, we present evidence that, relative to placebo, transdermal TRT can increase LBM and reduce FM over 3 – 36 months. The impact of TRT on bone mineral density and metabolism is also discussed, with particular relevance for persons with SCI. Moreover, the risks of TRT remain controversial and pertinent safety considerations related to transdermal administration are outlined. CONCLUSION: Further research is necessary to help develop clinical guidelines for the specific dose and duration of TRT in persons with SCI. Therefore, we call for more high-quality randomized controlled trials to examine the efficacy and safety of TRT in this population, who experience an increased risk of cardiometabolic diseases as a result of deleterious body composition changes after injury.",
keywords = "Testosterone replacement therapy, body composition, lean body mass, fat mass, spinal cord injury",
author = "Tom Nightingale and Pam Moore and Joshua Harman and Refka Khalil and Ranjodh Gill and Teodoro Castillo and Robert Adler and Ashraf Gorgey",
year = "2018",
month = nov,
day = "2",
doi = "10.1080/10790268.2017.1357917",
language = "English",
volume = "41",
pages = "624--636",
journal = "Journal of Spinal Cord Medicine",
issn = "1079-0268",
publisher = "Maney Publishing",
number = "6",

}

RIS

TY - JOUR

T1 - Body composition changes after testosterone replacement therapy following spinal cord injury and aging

T2 - a mini review

AU - Nightingale, Tom

AU - Moore, Pam

AU - Harman, Joshua

AU - Khalil, Refka

AU - Gill, Ranjodh

AU - Castillo, Teodoro

AU - Adler, Robert

AU - Gorgey, Ashraf

PY - 2018/11/2

Y1 - 2018/11/2

N2 - CONTEXT: Hypogonadism is a male clinical condition in which the body does not produce enough testosterone. Testosterone plays a key role in maintaining body composition, bone mineral density, sexual function, mood, erythropoiesis, cognition and quality of life. Hypogonadism can occur due to several underlying pathologies during aging and in men with physical disabilities, such as spinal cord injury (SCI). This condition is often under diagnosed and as a result, symptoms undertreated. METHODS: In this mini-review, we propose that testosterone replacement therapy (TRT) might be a viable strategy to improve lean body mass (LBM) and fat mass (FM) in men with SCI. EVIDENCE SYNTHESIS: Supplementing the limited data from SCI cohorts with consistent findings from studies in non-disabled aging men, we present evidence that, relative to placebo, transdermal TRT can increase LBM and reduce FM over 3 – 36 months. The impact of TRT on bone mineral density and metabolism is also discussed, with particular relevance for persons with SCI. Moreover, the risks of TRT remain controversial and pertinent safety considerations related to transdermal administration are outlined. CONCLUSION: Further research is necessary to help develop clinical guidelines for the specific dose and duration of TRT in persons with SCI. Therefore, we call for more high-quality randomized controlled trials to examine the efficacy and safety of TRT in this population, who experience an increased risk of cardiometabolic diseases as a result of deleterious body composition changes after injury.

AB - CONTEXT: Hypogonadism is a male clinical condition in which the body does not produce enough testosterone. Testosterone plays a key role in maintaining body composition, bone mineral density, sexual function, mood, erythropoiesis, cognition and quality of life. Hypogonadism can occur due to several underlying pathologies during aging and in men with physical disabilities, such as spinal cord injury (SCI). This condition is often under diagnosed and as a result, symptoms undertreated. METHODS: In this mini-review, we propose that testosterone replacement therapy (TRT) might be a viable strategy to improve lean body mass (LBM) and fat mass (FM) in men with SCI. EVIDENCE SYNTHESIS: Supplementing the limited data from SCI cohorts with consistent findings from studies in non-disabled aging men, we present evidence that, relative to placebo, transdermal TRT can increase LBM and reduce FM over 3 – 36 months. The impact of TRT on bone mineral density and metabolism is also discussed, with particular relevance for persons with SCI. Moreover, the risks of TRT remain controversial and pertinent safety considerations related to transdermal administration are outlined. CONCLUSION: Further research is necessary to help develop clinical guidelines for the specific dose and duration of TRT in persons with SCI. Therefore, we call for more high-quality randomized controlled trials to examine the efficacy and safety of TRT in this population, who experience an increased risk of cardiometabolic diseases as a result of deleterious body composition changes after injury.

KW - Testosterone replacement therapy

KW - body composition

KW - lean body mass

KW - fat mass

KW - spinal cord injury

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85055663152&partnerID=MN8TOARS

U2 - 10.1080/10790268.2017.1357917

DO - 10.1080/10790268.2017.1357917

M3 - Review article

VL - 41

SP - 624

EP - 636

JO - Journal of Spinal Cord Medicine

JF - Journal of Spinal Cord Medicine

SN - 1079-0268

IS - 6

ER -